Global Menopausal Hot Flashes Drug Market
Global Menopausal Hot Flashes Drug Market

Menopausal Hot Flashes Drug Comprehensive Study by Type (Capsule, Liniment, Tablet, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Treatment Type (Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination), Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine), Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others)) Players and Region - Global Market Outlook to 2026

Menopausal Hot Flashes Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 247 Pages 163 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Menopausal hot flashes drugs are used to reduce hot flashes, which is a form of temperature dysfunction that occurs due to changes in gonadal hormones. A hot flash is a sudden feeling of warmth, which is usually most intense over the chest, neck, and face. Hot flashes cause redness of the skin and excessive sweating. Hot flashes generally occur due to menopause when menstrual periods become irregular and eventually stop. Hot flashes cause due to changes in reproductive hormones which become more sensitive to slight changes in body temperature.This growth is primarily driven by Increasing Incidence of Menopausal Hot Flashes and High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women.

Globally, a noticeable market trend is evident Rising R&D in Treatment Options that Target the Brain’s Thermostat to Reduce the Incidence of Hot Flashes in Women. Major Players, such as Pfizer Inc. (United States), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Allergan plc (Ireland), Teva Pharmaceutical Industries Ltd. (Ireland), Mylan N.V. (United States), Hisamitsu Pharmaceutical Co., Inc. (Japan), Merck & Co., Inc. (United States), GlaxoSmithKline plc (United Kingdom), TherapeuticsMD, Inc (United States) and Bayer (Germany) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 6th August 2019, Astellas Pharma Inc. has announced the dosing of the first patient in the SKYLIGHT 1 Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for the treatment of moderate-to-severe vasomotor symptoms (VMS) – i.e., hot flashes and night sweats associated with menopause.
On 14th March 2018, Imperial College London has introduced a new class of experimental drugs that reduces hot flushes in menopausal women.

Market Drivers
  • Increasing Incidence of Menopausal Hot Flashes
  • High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women

Market Trend
  • Rising R&D in Treatment Options that Target the Brain’s Thermostat to Reduce the Incidence of Hot Flashes in Women

Restraints
  • Increased Risk of Breast Cancer with Estrogen-Progestin Use

Opportunities
Technological Advancements in the Development of New Drugs
Challenges
Strict Government Regulations

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Type
  • Capsule
  • Liniment
  • Tablet
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Treatment Type
  • Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination)
  • Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine)
  • Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Menopausal Hot Flashes
      • 3.2.2. High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Rising R&D in Treatment Options that Target the Brain’s Thermostat to Reduce the Incidence of Hot Flashes in Women
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Menopausal Hot Flashes Drug, by Type, Distribution Channel, Treatment Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Menopausal Hot Flashes Drug (Value)
      • 5.2.1. Global Menopausal Hot Flashes Drug by: Type (Value)
        • 5.2.1.1. Capsule
        • 5.2.1.2. Liniment
        • 5.2.1.3. Tablet
        • 5.2.1.4. Others
      • 5.2.2. Global Menopausal Hot Flashes Drug by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Menopausal Hot Flashes Drug by: Treatment Type (Value)
        • 5.2.3.1. Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination)
        • 5.2.3.2. Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine)
        • 5.2.3.3. Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others)
      • 5.2.4. Global Menopausal Hot Flashes Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Menopausal Hot Flashes Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk A/S (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. TherapeuticsMD, Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bayer (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Menopausal Hot Flashes Drug Sale, by Type, Distribution Channel, Treatment Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Menopausal Hot Flashes Drug (Value)
      • 7.2.1. Global Menopausal Hot Flashes Drug by: Type (Value)
        • 7.2.1.1. Capsule
        • 7.2.1.2. Liniment
        • 7.2.1.3. Tablet
        • 7.2.1.4. Others
      • 7.2.2. Global Menopausal Hot Flashes Drug by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Menopausal Hot Flashes Drug by: Treatment Type (Value)
        • 7.2.3.1. Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination)
        • 7.2.3.2. Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine)
        • 7.2.3.3. Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others)
      • 7.2.4. Global Menopausal Hot Flashes Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Menopausal Hot Flashes Drug: by Type(USD Million)
  • Table 2. Menopausal Hot Flashes Drug Capsule , by Region USD Million (2015-2020)
  • Table 3. Menopausal Hot Flashes Drug Liniment , by Region USD Million (2015-2020)
  • Table 4. Menopausal Hot Flashes Drug Tablet , by Region USD Million (2015-2020)
  • Table 5. Menopausal Hot Flashes Drug Others , by Region USD Million (2015-2020)
  • Table 6. Menopausal Hot Flashes Drug: by Distribution Channel(USD Million)
  • Table 7. Menopausal Hot Flashes Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Menopausal Hot Flashes Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Menopausal Hot Flashes Drug Online Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Menopausal Hot Flashes Drug: by Treatment Type(USD Million)
  • Table 11. Menopausal Hot Flashes Drug Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination) , by Region USD Million (2015-2020)
  • Table 12. Menopausal Hot Flashes Drug Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine) , by Region USD Million (2015-2020)
  • Table 13. Menopausal Hot Flashes Drug Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others) , by Region USD Million (2015-2020)
  • Table 14. South America Menopausal Hot Flashes Drug, by Country USD Million (2015-2020)
  • Table 15. South America Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 16. South America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 17. South America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 18. Brazil Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 19. Brazil Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 21. Argentina Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 22. Argentina Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 23. Argentina Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 24. Rest of South America Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 26. Rest of South America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 27. Asia Pacific Menopausal Hot Flashes Drug, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 31. China Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 32. China Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 33. China Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 34. Japan Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 35. Japan Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 36. Japan Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 37. India Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 38. India Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 39. India Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 40. South Korea Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 41. South Korea Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 42. South Korea Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 43. Taiwan Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 44. Taiwan Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 45. Taiwan Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 46. Australia Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 47. Australia Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 48. Australia Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 52. Europe Menopausal Hot Flashes Drug, by Country USD Million (2015-2020)
  • Table 53. Europe Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 54. Europe Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 56. Germany Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 57. Germany Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 58. Germany Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 59. France Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 60. France Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 61. France Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 62. Italy Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 63. Italy Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 64. Italy Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 65. United Kingdom Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 67. United Kingdom Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 68. Netherlands Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 69. Netherlands Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 70. Netherlands Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 71. Rest of Europe Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Europe Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 74. MEA Menopausal Hot Flashes Drug, by Country USD Million (2015-2020)
  • Table 75. MEA Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 76. MEA Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 78. Middle East Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 79. Middle East Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 80. Middle East Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 81. Africa Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 82. Africa Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 83. Africa Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 84. North America Menopausal Hot Flashes Drug, by Country USD Million (2015-2020)
  • Table 85. North America Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 86. North America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 88. United States Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 89. United States Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 90. United States Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 91. Canada Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 92. Canada Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 93. Canada Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 94. Mexico Menopausal Hot Flashes Drug, by Type USD Million (2015-2020)
  • Table 95. Mexico Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2015-2020)
  • Table 96. Mexico Menopausal Hot Flashes Drug, by Treatment Type USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Menopausal Hot Flashes Drug: by Type(USD Million)
  • Table 109. Menopausal Hot Flashes Drug Capsule , by Region USD Million (2021-2026)
  • Table 110. Menopausal Hot Flashes Drug Liniment , by Region USD Million (2021-2026)
  • Table 111. Menopausal Hot Flashes Drug Tablet , by Region USD Million (2021-2026)
  • Table 112. Menopausal Hot Flashes Drug Others , by Region USD Million (2021-2026)
  • Table 113. Menopausal Hot Flashes Drug: by Distribution Channel(USD Million)
  • Table 114. Menopausal Hot Flashes Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 115. Menopausal Hot Flashes Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 116. Menopausal Hot Flashes Drug Online Pharmacies , by Region USD Million (2021-2026)
  • Table 117. Menopausal Hot Flashes Drug: by Treatment Type(USD Million)
  • Table 118. Menopausal Hot Flashes Drug Hormonal Treatment (Estrogen, Progesterone, and Estrogen–Progesterone Combination) , by Region USD Million (2021-2026)
  • Table 119. Menopausal Hot Flashes Drug Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, and Clonidine) , by Region USD Million (2021-2026)
  • Table 120. Menopausal Hot Flashes Drug Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, and Others) , by Region USD Million (2021-2026)
  • Table 121. South America Menopausal Hot Flashes Drug, by Country USD Million (2021-2026)
  • Table 122. South America Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 123. South America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 124. South America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 125. Brazil Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 126. Brazil Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 127. Brazil Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 128. Argentina Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 129. Argentina Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 130. Argentina Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 131. Rest of South America Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 132. Rest of South America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 133. Rest of South America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 134. Asia Pacific Menopausal Hot Flashes Drug, by Country USD Million (2021-2026)
  • Table 135. Asia Pacific Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 136. Asia Pacific Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 137. Asia Pacific Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 138. China Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 139. China Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 140. China Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 141. Japan Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 142. Japan Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 143. Japan Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 144. India Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 145. India Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 146. India Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 147. South Korea Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 148. South Korea Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 149. South Korea Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 150. Taiwan Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 151. Taiwan Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 152. Taiwan Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 153. Australia Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 154. Australia Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 155. Australia Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 159. Europe Menopausal Hot Flashes Drug, by Country USD Million (2021-2026)
  • Table 160. Europe Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 161. Europe Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 162. Europe Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 163. Germany Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 164. Germany Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 165. Germany Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 166. France Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 167. France Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 168. France Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 169. Italy Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 170. Italy Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 171. Italy Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 172. United Kingdom Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 173. United Kingdom Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 174. United Kingdom Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 175. Netherlands Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 176. Netherlands Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 177. Netherlands Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 178. Rest of Europe Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 179. Rest of Europe Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 180. Rest of Europe Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 181. MEA Menopausal Hot Flashes Drug, by Country USD Million (2021-2026)
  • Table 182. MEA Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 183. MEA Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 184. MEA Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 185. Middle East Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 186. Middle East Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 187. Middle East Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 188. Africa Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 189. Africa Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 190. Africa Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 191. North America Menopausal Hot Flashes Drug, by Country USD Million (2021-2026)
  • Table 192. North America Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 193. North America Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 194. North America Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 195. United States Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 196. United States Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 197. United States Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 198. Canada Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 199. Canada Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 200. Canada Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 201. Mexico Menopausal Hot Flashes Drug, by Type USD Million (2021-2026)
  • Table 202. Mexico Menopausal Hot Flashes Drug, by Distribution Channel USD Million (2021-2026)
  • Table 203. Mexico Menopausal Hot Flashes Drug, by Treatment Type USD Million (2021-2026)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Menopausal Hot Flashes Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Menopausal Hot Flashes Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Menopausal Hot Flashes Drug: by Treatment Type USD Million (2015-2020)
  • Figure 7. South America Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 8. Asia Pacific Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 9. Europe Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 10. MEA Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 11. North America Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 12. Global Menopausal Hot Flashes Drug share by Players 2020 (%)
  • Figure 13. Global Menopausal Hot Flashes Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Menopausal Hot Flashes Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 21. Novo Nordisk A/S (Denmark) Revenue: by Geography 2020
  • Figure 22. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Ireland) Revenue: by Geography 2020
  • Figure 26. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 28. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2020
  • Figure 30. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 34. TherapeuticsMD, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. TherapeuticsMD, Inc (United States) Revenue: by Geography 2020
  • Figure 36. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Bayer (Germany) Revenue: by Geography 2020
  • Figure 38. Global Menopausal Hot Flashes Drug: by Type USD Million (2021-2026)
  • Figure 39. Global Menopausal Hot Flashes Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 40. Global Menopausal Hot Flashes Drug: by Treatment Type USD Million (2021-2026)
  • Figure 41. South America Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 42. Asia Pacific Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 43. Europe Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 44. MEA Menopausal Hot Flashes Drug Share (%), by Country
  • Figure 45. North America Menopausal Hot Flashes Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Allergan plc (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Mylan N.V. (United States)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Merck & Co., Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • TherapeuticsMD, Inc (United States)
  • Bayer (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation